ZA
SUPN icon

Zazove Associates’s Supernus Pharmaceuticals SUPN Stock Holding History

Zazove Associates’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-138,429
Closed -$1.67M – 125
2015
Q1 		$1.67M Buy
+138,429
New +$1.31M 0.08% 81

Other funds holding SUPN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
MRM
Michael R. Murphy $255M AUM 0.87% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return

Zazove Associates's SUPN Position: Q2 2015 in Review

Zazove Associates sold out of Supernus Pharmaceuticals (SUPN) in Q2 2015, closing a stake of 138,429 shares — an estimated $1.67M sold.

Zazove Associates first reported a position in SUPN in Q1 2015 and held it in 1 quarter. The position peaked at $1.67M in Q1 2015. 166 funds tracked by Wall St. Rank hold SUPN as of Q2 2015.

  • Zazove Associates reported no remaining Supernus Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Zazove Associates sold 138,429 Supernus Pharmaceuticals shares in Q2 2015, an estimated $1.67M.
  • Zazove Associates first reported a position in Supernus Pharmaceuticals in Q1 2015 and held it in 1 quarter.
  • Zazove Associates's Supernus Pharmaceuticals position peaked at $1.67M in Q1 2015.
  • 166 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2015.

Based on Zazove Associates's 13F filing for Q2 2015, filed 10 Aug 2015.